Clinical implications of apoptosis in ischemic myocardium - PubMed (original) (raw)
Review
Clinical implications of apoptosis in ischemic myocardium
Tiziano M Scarabelli et al. Curr Probl Cardiol. 2006 Mar.
Abstract
Apoptosis, a genetically programmed form of cell death, contributes to myocyte cell loss in a variety of cardiac pathologies, including cardiac failure and those related to ischemia/reperfusion injury. The apoptotic program is complex, involving both pro- and anti-apoptotic proteins, and apoptosis occurs when the equilibrium between these opposing factors is perturbed. Some of these factors are intrinsic to the apoptotic pathway, such as the pro- and anti-apoptotic members of the Bcl2 family. Other, extrinsic, cellular factors can also modify the outcome of the response to an apoptotic stimulus. In this review, we have focused on some of these extrinsic factors, such as STAT-1 as a pro-apoptotic agent and the urocortins and Bag-1 as anti-apoptotic factors, since these may be potential therapeutic targets. In addition, we discuss the profound cytoprotective effects of the antibiotic, minocycline.
Similar articles
- STAT signalling in the heart and cardioprotection.
Soond SM, Latchman DS, Stephanou A. Soond SM, et al. Expert Rev Mol Med. 2006 Jul 12;8(15):1-16. doi: 10.1017/S1462399406000032. Expert Rev Mol Med. 2006. PMID: 16836797 Review. - Activated STAT-1 pathway in the myocardium as a novel therapeutic target in ischaemia/reperfusion injury.
Stephanou A. Stephanou A. Eur Cytokine Netw. 2002 Oct-Dec;13(4):401-3. Eur Cytokine Netw. 2002. PMID: 12517719 Review. - Myocardial ischemia and reperfusion injury.
Buja LM. Buja LM. Cardiovasc Pathol. 2005 Jul-Aug;14(4):170-5. doi: 10.1016/j.carpath.2005.03.006. Cardiovasc Pathol. 2005. PMID: 16009313 Review. - Role of apoptosis in reperfusion injury.
Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ, Doevendans PA. Eefting F, et al. Cardiovasc Res. 2004 Feb 15;61(3):414-26. doi: 10.1016/j.cardiores.2003.12.023. Cardiovasc Res. 2004. PMID: 14962473 Review. - Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
Ferdinandy P, Schulz R, Baxter GF. Ferdinandy P, et al. Pharmacol Rev. 2007 Dec;59(4):418-58. doi: 10.1124/pr.107.06002. Epub 2007 Nov 29. Pharmacol Rev. 2007. PMID: 18048761 Review.
Cited by
- Expression of insulin-like growth factor binding protein-3 in HELLP syndrome.
Wei L, Liping Z, Suya K. Wei L, et al. BMC Pregnancy Childbirth. 2023 Nov 10;23(1):778. doi: 10.1186/s12884-023-06074-7. BMC Pregnancy Childbirth. 2023. PMID: 37950229 Free PMC article. - Synergistic cardioprotective effects of Danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway.
Hu T, Wei G, Xi M, Yan J, Wu X, Wang Y, Zhu Y, Wang C, Wen A. Hu T, et al. Int J Mol Med. 2016 Jul;38(1):83-94. doi: 10.3892/ijmm.2016.2584. Epub 2016 May 11. Int J Mol Med. 2016. PMID: 27176815 Free PMC article. - Ischemic preconditioning: protection against myocardial necrosis and apoptosis.
Iliodromitis EK, Lazou A, Kremastinos DT. Iliodromitis EK, et al. Vasc Health Risk Manag. 2007;3(5):629-37. Vasc Health Risk Manag. 2007. PMID: 18078014 Free PMC article. Review. - Nuclear and mitochondrial signalling Akts in cardiomyocytes.
Miyamoto S, Rubio M, Sussman MA. Miyamoto S, et al. Cardiovasc Res. 2009 May 1;82(2):272-85. doi: 10.1093/cvr/cvp087. Epub 2009 Mar 11. Cardiovasc Res. 2009. PMID: 19279164 Free PMC article. Review. - Toward microRNA-based therapeutics for heart disease: the sense in antisense.
van Rooij E, Marshall WS, Olson EN. van Rooij E, et al. Circ Res. 2008 Oct 24;103(9):919-28. doi: 10.1161/CIRCRESAHA.108.183426. Circ Res. 2008. PMID: 18948630 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous